Most companies are, by definition, mediocre. Some are good. Fewer still are great. And a tiny minority are truly exceptional. These are the ones I want to own. I’m looking to invest in durable, adaptable and – above all – resilient businesses; those selling critical goods and services, with high levels of recurring income from loyal customers. I believe the three companies below pass these tests with flying colours.
Experian (LSE: EXPN) owns the world’s largest credit bureau. It aggregates credit data from lenders, then sells it back to them. Without this data, banks would not be able to lend and the world economy would grind to a halt. Experian has successfully expanded into new applications, using its data in more ways to solve more problems for more customers in more industries.
Today, it helps over 180 million consumers take control of their finances. It assists over 150,000 businesses, not only with lending decisions, but in verifying online purchases, combatting fraud, acquiring customers and becoming more efficient. It even helps US hospitals manage payments.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This evolution has been reinforced by significant investments in innovation, from its insurance marketplace allowing US consumers to search and apply for car insurance with a few clicks, to its major investments in analytics tools and software. The roll-out of these recently launched products has only just begun. And it could meaningfully accelerate Experian’s revenue and profit growth over the next decade. I’ve never been so excited by its long-term prospects.
Danaher Corporation: a top "picks and shovels" play
In the California gold rush, it wasn’t the gold miners who made the most money. It was the companies supplying the picks and shovels. Danaher Corporation (NYSE: DHR) has positioned itself as the picks-and-shovels provider to the medical-science industry.
The company provides diagnostic tests, life-sciences instruments and technologies for the development, manufacture and delivery of biological drugs. The diversity of its product portfolio, leadership positions in highly regulated markets and global scale add up to a resilient business that is difficult to compete with.
That said, it hasn’t been plain sailing in recent years. The pandemic saw a boom in spending from pharmaceutical and biotechnology companies. When that trend reversed and these companies cut back on inventories, Danaher’s revenue and profit took a hit. The good news is that demand for biological therapies is still growing rapidly. And with most of Danaher’s customers having worked through excess inventories and returned to normal ordering patterns, the stage could be set for a return to growth.
I highlighted Roper Technologies (Nasdaq: ROP) as one of my favourite shares last year for MoneyWeek. I have chosen to do so again because I believe the firm is at an interesting juncture. Roper owns 28 high-quality software and technology businesses, generating excellent margins and cash flow, and has a strong record of acquisitions and disposals.
But 2024 wasn’t a vintage year. Tough market conditions for a few of its business subsidiaries held back organic growth. Those headwinds now appear to be easing and beneath the surface it is making excellent strides. Having disposed of its more cyclical businesses, Roper is now attempting to get the most out of its existing operations. This includes a sharper focus on strategy, talent and new product development, such as incorporating generative AI into its software solutions.
Roper’s acquisition strategy is also evolving. There is a greater focus on “bolt-on” deals that can be assimilated into existing firms, and buying businesses at a slightly earlier stage of their development, with stronger growth prospects. In short, I think Roper’s mid- to long-term growth prospects are improving. This could be the year that progress becomes more evident.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Barclays begins paying up to £100 compensation to customers after banking outageBarclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
-
Review: Shangri-La Paris – an ode to the world’s best foodNatasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
